NEZELOF AWARD IN BASIC SCIENCE
In order to stimulate the activities of scientists and clinicians from around the world studying the histiocytic disorders, the Histiocyte Society is sponsoring an annual prize for the best scientific article at the Annual Meeting. The Award will be given in honor of Dr. Christian Nezelof, renowned pathologist, investigator, teacher, founding member and first President of the Society, to a physician or scientist who is carrying out basic research on the therapy, biology or pathogenesis of one of the histiocytic disorders.
Dr. Christian Nezelof studied medicine in Paris, France during and after the Second World War. In 1948 he specialized in Pediatrics at the Hôpital des Enfants Malades. In the early fifties, as a young pediatrician, he published the first clinical report on cystic fibrosis in France. In 1956 he worked in the Department of Pathology at the Sick Children Hospital in London under the direction of Professor Bodian, a famous British pathologist who first described cystic fibrosis in children. On returning to France he completed training in Pediatric Pathology. During the period from 1960-1968 Dr. Nezelof served as a full-time pathologist at Necker-Enfants Malades, where he became Chairman of the Department of Pathology in 1968. In parallel, from 1970, for 15 years he was Head of INSERM Research Unit and created the Groups of Pediatric Pathology located at the Necker-Enfants Malades Hospital.
The many contributions by Dr. Nezelof include:
Histiocytic disorders continue to be one of his major fields of interest. In 1982 Dr. Nezelof described the successful growth in nude mice of a tumor after injection of cells from the pleural effusion of a child with malignant histiocytosis. After this manuscript entitled: "Tumor cell line characterization of a malignant histiocytosis transplanted into nude mice" his team has described successful establishment in vitro of the Malignant Histiocytosis DEL cell line.
RUXOLITINIB OVERCOMES CYTOKINE-INDUCED DEXAMETHASONE RESISTANCE IN ACTIVATED CYTOTOXIC T-LYMPHOCYTES: IMPLICATIONS FOR THE USE OF RUXOLITINIB IN REFRACTORY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
A NOVEL CTL-BASED FUNCTIONAL ASSAY REVEALS A STRONG CORRELATION BETWEEN THE PATHOGENICITY OF AN UNC13D VARIANT AND THE INSTABILITY OF ITS TRANSLATED MUNC13-4 PROTEIN; MUNC13-4 PROTEIN EXPRESSION ASSAY IS A RELIABLE METHOD FOR IDENTIFICATION OF PATIENTS WITH FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 3
About the Society
The Histiocyte Society is a nonprofit organization of more than 200 physicians and scientists from around the world committed to improving the lives of patients with histiocytic disorders by conducting clinical and laboratory research into the causes and treatment of this disease.
Copyright © 2020 Histiocyte Society